Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

367 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Inhibition of CBP/β-catenin signaling ameliorated fibrosis in cholestatic liver disease.
Kimura M, Nishikawa K, Osawa Y, Imamura J, Yamaji K, Harada K, Yatsuhashi H, Murata K, Miura K, Tanaka A, Kanto T, Kohara M, Kamisawa T, Kimura K. Kimura M, et al. Among authors: kamisawa t. Hepatol Commun. 2022 Oct;6(10):2732-2747. doi: 10.1002/hep4.2043. Epub 2022 Jul 20. Hepatol Commun. 2022. PMID: 35855613 Free PMC article.
Clinical diagnostic criteria for IgG4-related sclerosing cholangitis 2020: (Revision of the clinical diagnostic criteria for IgG4-related sclerosing cholangitis 2012).
Nakazawa T, Kamisawa T, Okazaki K, Kawa S, Tazuma S, Nishino T, Inoue D, Naitoh I, Watanabe T, Notohara K, Kubota K, Ohara H, Tanaka A, Takikawa H, Masamune A, Unno M. Nakazawa T, et al. Among authors: kamisawa t. J Hepatobiliary Pancreat Sci. 2021 Mar;28(3):235-242. doi: 10.1002/jhbp.913. Epub 2021 Feb 26. J Hepatobiliary Pancreat Sci. 2021. PMID: 33586343
Safety, tolerability, and anti-fibrotic efficacy of the CBP/β-catenin inhibitor PRI-724 in patients with hepatitis C and B virus-induced liver cirrhosis: An investigator-initiated, open-label, non-randomised, multicentre, phase 1/2a study.
Kimura K, Kanto T, Shimoda S, Harada K, Kimura M, Nishikawa K, Imamura J, Ogawa E, Saio M, Ikura Y, Okusaka T, Inoue K, Ishikawa T, Ieiri I, Kishimoto J, Todaka K, Kamisawa T. Kimura K, et al. Among authors: kamisawa t. EBioMedicine. 2022 Jun;80:104069. doi: 10.1016/j.ebiom.2022.104069. Epub 2022 May 20. EBioMedicine. 2022. PMID: 35605429 Free PMC article. Clinical Trial.
Reducing relapse through maintenance steroid treatment can decrease the cancer risk in patients with IgG4-sclerosing cholangitis: Based on a Japanese nationwide study.
Kubota K, Kamisawa T, Nakazawa T, Tanaka A, Naitoh I, Kurita Y, Takikawa H, Unno M, Kawa S, Masamune A, Nakamura S, Okazaki K; Collaborators. Kubota K, et al. Among authors: kamisawa t. J Gastroenterol Hepatol. 2023 Apr;38(4):556-564. doi: 10.1111/jgh.16066. Epub 2023 Jan 10. J Gastroenterol Hepatol. 2023. PMID: 36403136
Clinical guidelines for primary sclerosing cholangitis 2017.
Isayama H, Tazuma S, Kokudo N, Tanaka A, Tsuyuguchi T, Nakazawa T, Notohara K, Mizuno S, Akamatsu N, Serikawa M, Naitoh I, Hirooka Y, Wakai T, Itoi T, Ebata T, Okaniwa S, Kamisawa T, Kawashima H, Kanno A, Kubota K, Tabata M, Unno M, Takikawa H; PSC guideline committee Members: Ministry of Health, Labour and Welfare (Japan) Research Project, The Intractable Hepatobiliary Disease Study Group. Isayama H, et al. Among authors: kamisawa t. J Gastroenterol. 2018 Sep;53(9):1006-1034. doi: 10.1007/s00535-018-1484-9. Epub 2018 Jun 27. J Gastroenterol. 2018. PMID: 29951926 Free PMC article.
Clinical practice guidelines for IgG4-related sclerosing cholangitis.
Kamisawa T, Nakazawa T, Tazuma S, Zen Y, Tanaka A, Ohara H, Muraki T, Inui K, Inoue D, Nishino T, Naitoh I, Itoi T, Notohara K, Kanno A, Kubota K, Hirano K, Isayama H, Shimizu K, Tsuyuguchi T, Shimosegawa T, Kawa S, Chiba T, Okazaki K, Takikawa H, Kimura W, Unno M, Yoshida M. Kamisawa T, et al. J Hepatobiliary Pancreat Sci. 2019 Jan;26(1):9-42. doi: 10.1002/jhbp.596. Epub 2019 Jan 18. J Hepatobiliary Pancreat Sci. 2019. PMID: 30575336 Free PMC article.
Correction to: Clinical guidelines for primary sclerosing cholangitis 2017.
Isayama H, Tazuma S, Kokudo N, Tanaka A, Tsuyuguchi T, Nakazawa T, Notohara K, Mizuno S, Akamatsu N, Serikawa M, Naitoh I, Hirooka Y, Wakai T, Itoi T, Ebata T, Okaniwa S, Kamisawa T, Kawashima H, Kanno A, Kubota K, Tabata M, Unno M, Takikawa H; PSC guideline committee Members: Ministry of Health, Labour and Welfare (Japan) Research Project, The Intractable Hepatobiliary Disease Study Group. Isayama H, et al. Among authors: kamisawa t. J Gastroenterol. 2022 Jun;57(6):453-454. doi: 10.1007/s00535-022-01867-7. J Gastroenterol. 2022. PMID: 35294681 Free PMC article. No abstract available.
Steroid therapy still plays a crucial role and could serve as a bridge to the next promising treatments in patients with IgG4-related sclerosing cholangitis: Results of a Japanese Nationwide Study.
Kubota K, Kamisawa T, Nakazawa T, Tanaka A, Naitoh I, Takikawa H, Unno M, Kawa S, Masamune A, Nakamura S, Okazaki K; Collaborators. Kubota K, et al. Among authors: kamisawa t. J Hepatobiliary Pancreat Sci. 2022 Apr 22. doi: 10.1002/jhbp.1157. Online ahead of print. J Hepatobiliary Pancreat Sci. 2022. PMID: 35460190
Short-term and long-term outcomes of autoimmune pancreatitis.
Takuma K, Kamisawa T, Tabata T, Inaba Y, Egawa N, Igarashi Y. Takuma K, et al. Among authors: kamisawa t. Eur J Gastroenterol Hepatol. 2011 Feb;23(2):146-52. doi: 10.1097/meg.0b013e3283431e23. Eur J Gastroenterol Hepatol. 2011. PMID: 21287714
367 results